Telemonitoring in COPD patients

Home Telemonitoring in Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON21302

Enrollment

178

Registered

2020-07-08

Start date

2020-06-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

This present study is an unblinded prospective randomized controlled trial with 12-months follow up in a Teaching Hospital (Deventer Ziekenhuis). The control group receives care as usual. The interven

Eligibility

Inclusion criteria

Inclusion criteria: ? COPD GOLD grade B or D ? Having access to and being able to use a mobile phone (Android/Iphone) or Tablet/iPad ? Native language: Dutch

Exclusion criteria

Exclusion criteria: ? Hospitalized patients ? Inability to give written informed consent ? The patient does not have WiFi at home

Design outcomes

Primary

Measure	Time frame
Level of self-management as measured with the Patient Activation Measure (PAM-13) at baseline, 3, 6 and 12 months	—

Secondary

Measure	Time frame
? Quality of Life (measured with EQ-5D-5L at baseline, 3, 6 and 12 months) ? Patient satisfaction (measured with CSQ-8 at baseline, 3, 6 and 12 months) ? Physical activity (number of steps each day during one week at baseline, 3, 6 and 12 months) ? Number of exacerbations (mild and severe) ? Number of hospital admissions ? Number of ED visits ? Length of hospital stay ? Health status (CCQ) ? Prescription rate of systematic corticosteroids and/or antibiotics ? Mortality during follow-up ? Loss to follow-up Parameters evaluated in intervention group only ? Patient adherence to telemonitoring ? Number of video consultations	—

Measure

Time frame

? Quality of Life (measured with EQ-5D-5L at baseline, 3, 6 and 12 months) ? Patient satisfaction (measured with CSQ-8 at baseline, 3, 6 and 12 months) ? Physical activity (number of steps each day during one week at baseline, 3, 6 and 12 months) ? Number of exacerbations (mild and severe) ? Number of hospital admissions ? Number of ED visits ? Length of hospital stay ? Health status (CCQ) ? Prescription rate of systematic corticosteroids and/or antibiotics ? Mortality during follow-up ? Loss to follow-up Parameters evaluated in intervention group only ? Patient adherence to telemonitoring ? Number of video consultations

—

Contacts

Public ContactKarin Groenewegen-Sipkema

Deventer Ziekenhuis

K.H.Groenewegen-Sipkema@dz.nl0570-535100

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)